

## SINON CORPORATION

23, Sec. 1, Mei Chuan W.Road, Taichung 403, Taiwan

TFL: 886-4-23726181

FAX: 886-4-23750574

http://www.sinon.com.tw H-mail-service@sinon.com.tw

K040320 page 1 of 2

### **510(k) SUMMARY** "

Submitter's Name: SINON Corporation

No. 23, Sec. 1, Mei Chuan W. Road, Taichung, 403, Taiwan, ROC

Date summary prepared:

February 2, 2004

Device Name:

Proprietary Name:

SINON Power Wheelchair, SN-P401

Common or Usual Name:

Powered Wheelchair

Classification Name:

Powered Wheelchair, Class II,

21 CFR 890.3860

#### Indications for Use:

The device is intended for medical purposes to provide mobility to persons restricted to a seated position.

#### Description of the device:

The SINON Power Wheelchair, SN-P401 is an indoor / outdoor Powered Wheelchair that is battery operated. It has a base with four-wheeled with a seat. The movement of the Wheelchair is controlled by the rider who uses hand controls located at the top of the steering column. The device can be disassembled for transport and is provided with an onboard battery charger.

#### Performance Testing:

EMC Report ANSI / RESNA WC/Vol.2-1998, CISPR 11: 1990, EN61000-3-2: 1995, IEC61000-3-3: 1995 (Electrically Powered Wheelchairs, controller, and their chargers – requirements and test methods)

Legally marketed device for substantial equivalence comparison:

EPW Power Wheelchair GP-201 (K023148)



# K040320 page 2012 SINON CORPORATION

23, Sec. 1, Mei Chuan W.Road, Taichung 403, Taiwan

TEL: 886-4-23726181

FAX: 886-4-23750574

http://www.sinon.com.tw E-mail-service@sinon.com.tw

Summary for substantial equivalence comparison:

The electronic systems between two devices are the same and all passed by the UL certificated, for instance the electronic controller, batteries and recharge. same safety level for the two devices is assured. The major differences existing of the two Powered Wheelchairs are the different batteries, and the overall dimension, the size of tires, and the weight are differences between the two devices. The overall appearance differences are not safety aspect. So the new device is substantially equivalent to the predicate devices in this aspect.



MAR 1 2 2004

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Sinon Corporation C/o Dr. Ke-Min Jen ROC Chinese-European Industrial Research Society No. 58, Fu-Chiun St. Hsin-Chu City, China (Taiwan) 300

Re: K040320

Trade/Device Name: SINON Power Wheelchair, SN-P401

Regulation Number: 21 CFR 890.3860 Regulation Name: Powered wheelchair

Regulatory Class: II Product Code: ITI

Dated: February 2, 2004 Received: February 9, 2004

#### Dear Dr. Jen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <a href="http://www.fda.gov/cdrh/dsma/dsmamain.html">http://www.fda.gov/cdrh/dsma/dsmamain.html</a>

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

<b>D</b>	1	- C	1
Page		$\alpha$ r	
l azc	1	O1	

510 (K) NUMBER ( IF KNOW ): TBA K040320
DEVICE NAME: <u>SINON Power Wheelchair, SN-P401</u>
INDICATIONS FOR USE:
The device is intended for medical purposes to provide mobility to persons restricted to
a sitting position.
(Division Sign-Off) Division of General, Restorative, and Neurological Devices
510(k) Yumber <u>K0<b>4</b></u> 0320
( PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE )
Concurrence of CDRH, office of Device Evaluation (ODE)
· · · · · · · · · · · · · · · · · · ·
Prescription Use OR Over—The—Counter—Use
(Per 21 CFR 801.109) (Optional Format 1-2-96)